Previous 10 | Next 10 |
Calliditas Therapeutics (NASDAQ:CALT) +38% on FDA approval for kidney disease therapy. Kaixin Auto (NASDAQ:KXIN) +27% on a partnership agreement with Bujia for 10k new energy trucks. Biomerica (NASDAQ:BMRA) +18% preliminary second quarter revenue increase of approxima...
“Medical treatment has made astonishing advances over the years. But the packaging and delivery of that treatment are often inefficient, ineffective, and consumer unfriendly.” That’s what Harvard researchers stated in Why Innovation in Health Care Is So Hard ...
atai Impact’s first major initiative will support promising academics in researching the therapeutic potential of psychedelic compounds to address unmet needs in mental health The Fund aims to help unlock the mysteries of the brain, improve the treatment of mental health ...
atai Life Sciences (ATAI -23.4%) discloses that a group of largest pre-IPO investors representing over 30% of the company’s common stock have voluntarily agreed for renewed lock-up agreements extending the trading restrictions of pre-IPO shares for up to 24 months. Among them is Apeiro...
Gainers: Biofrontera (NASDAQ:BFRI) +26%, Gemini Therapeutics (NASDAQ:GMTX) +19%, Vir Biotechnology (NASDAQ:VIR) +14%, Mesoblast (NASDAQ:MESO) +14%, Tandem Diabetes Care (NASDAQ:TNDM) +10% Losers: Atai Life Sciences (NASDAQ:ATAI) -24%, Alzamend...
• Apeiron and other key shareholders enter into voluntary lock-up agreements • This voluntary lock-up extends trading restrictions by 24 months for Apeiron and 12 months for other investors • Demonstrates strong ongoing confidence in atai’...
Palm Beach, FL –December 14, 2021 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially, and the development of novel medications has not kept pace, precipitating a crisis in psychiatric medicine. A nove...
RL-007 was well tolerated and demonstrated a clinically meaningful pro-cognitive profile Changes in quantitative electroencephalogram (qEEG) were consistent with the results of a previous Phase 1 trial of RL-007 These results support the progression of RL-007 to a do...
NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has been selected for addition to the Nasdaq Biotechnology I...
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentatio...
News, Short Squeeze, Breakout and More Instantly...
ATAI Life Sciences N.V. Company Name:
ATAI Stock Symbol:
NASDAQ Market:
ATAI Life Sciences N.V. Website:
Alcohol use disorder is a disorder characterized by an inability to stop or control one’s drinking despite adverse health, occupational or social consequences. Conventional treatments include medication, behavioral therapy, and support groups. Even with these treatments, however, many ind...
Psychedelics such as DMT, LSD and psilocybin have demonstrated promise in the treatment of affective symptoms of a range of disorders. These drugs work by inducing an altered state of consciousness , which includes intensified perceptions and emotions, which have been associated with therapeutic...